Vertebral osteomyelitis due to Candida species
We have noted an increased number of cases of vertebral osteomyelitis secondary to Candida species over the past few years at our facility. Our aim was to identify and review these cases to elucidate risk factors, treatment regimens and outcomes.
We performed a retrospective chart review using our electronic medical record and microbiology laboratory database to identify cases of vertebral osteomyelitis due to Candida at a single teaching hospital from 2006–2018.
We found 15 cases of Candida vertebral osteomyelitis. The majority of cases were due to Candida albicans and affected either the lumbar or the thoracic spine. Injection drug use and previous spine surgery were the two most common risk factors identified. Treatment was largely with intravenous antifungal induction followed by prolonged therapy with oral fluconazole. There was no short-term mortality though we lacked long-term follow-up on most patients.
The number of vertebral infections due to Candida may be increasing. This may be partially driven by both a rise in intravenous drug use as well as the growing rate of spine surgery. Management following currently available guidelines seems favorable, though further studies are necessary to determine the optimal treatment regimen.
KeywordsCandida Vertebral osteomyelitis Diskitis Injection drug use Candida infections
Compliance with ethical standards
Conflict of interest
The authors have no competing interest.
West Virginia University Institutional Review Board approved this study.
No informed consent was required due to the retrospective nature of this study and no patient identifying information was utilized in this publication.
- 4.National Institute on Drug Abuse. West Virginia opioid summary. NIDA. http://www.drugabuse.gov/drugs-abuse/opioids/opioid-summaries-by-state/west-virginia-opioid-summary. Accessed 28 Feb 2018.